

DRUG DISCOVERY & DEVELOPMENT

FEBRUARY 24, 2021

| Date | Time | Track | Presentation Title | Speaker |
|--------|---------------------------|---|--|---|
| 24-Feb | 06:00 - 07:00 AM | Novel Advancements to Clinical Development | Fueling Discovery: Next-generation isolation of PBMCs and primary cells from Miltenyi Biotec | Josh Mahlios, PhD Senior Marketing Product Manager, Miltenyi Biotec |
| 24-Feb | 06:00 - 07:00 AM | | Introducing GenScript's DNA-Encoded Chemical Library Kit - GenDECL | Rouba Najjar, MBA Head of US Marketing and Business Development, Products Division |
| 24-Feb | 07:30 - 08:30 AM | Innovative Biomarkers in Drug Development | Keynote Presentation: The biomarker to companion diagnostic continuum: a road map for the delivery of precision medicine | Steven M. Anderson, PhD Chief Scientific Officer, Covance Drug Development |
| 24-Feb | 09:00 - 10:00 AM | Innovative Biomarkers in Drug Development | Keynote Panel Presentation: Biomarker assays - bioanalytical meets CLIA | Roger Hayes, PhD Vice President, Bioanalytical Services, ICON Laboratory Services Andrew Roche, PhD Senior Director, Scientific Affairs, ICON Laboratory Services |
| 24-Feb | 10:30 - 11:30 AM | | The New xMAP® INTELLIFLEX: Technology You Trust. Versatility You Want | Sherry A. Dunbar, PhD, MBA Senior Director, Global Scientific Affairs Josh Jenkins, MS Sales Development Manager, Licensed Technologies Group, Luminex Corporation |
| 24-Feb | 10:30 - 11:30 AM | New Practices in Early Phase Drug Discovery | The Visiopharm Platform: Flexible tools to solve real-world problems | Keith Bowers, PhD Senior Business Development Manager, OracleBio Dave Mason, PhD Technical Sales Specialist, Visiopharm |

| | | | | |
|--------|---------------------------|---|---|--|
| 24-Feb | 12:00 - 01:00 PM | New Practices in Early Phase Drug Discovery | Deep Mechanistic profiling of immune oncology drug combinations in cancer patients with CIVO intratumoral micro-dosing and NanoString's GeoMx® Digital Spatial Profiler | Jason Frazier Director of Scientific Operations, Presage Biosciences Sarah Warren, PhD Sr Director of Translational Science, NanoString Technologies |
| 24-Feb | 12:00 - 01:00 PM | New Practices in Early Phase Drug Discovery | Speed up your drug discovery with ready-to-use stable cell lines | Vevian Zhang Product Manager, GenScript |
| 24-Feb | 01:30 - 02:30 PM | New Practices in Early Phase Drug Discovery | Roundtable Panel Presentation: Recent Trends in Screening GPCRs | Annette Gilchrist, PhD Associate-Professor, Pharmaceutical Sciences, Midwestern University Professor Kevin Pflieger, MA, PhD, FBPhS Director, Biomedical and Health Innovation, The University of Western Australia and WA Life Sciences Innovation Hub; President, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT); Head, Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research (Centre for Medical Research, The University of Western Australia); Deputy Director & UWA Node Leader, ARC Centre for Personalised Therapeutics Technologies Juan José Fung, PhD Principal Scientist, GPCR Therapeutics Aarti Kawatkar Sr. Scientist, Chemical Biology and Proteomics group, AstraZeneca Yamina A. Berchiche, PhD Founder, Dr. GPCR Ajay Yekkirala, PhD Co-Founder & CSO, Blue Therapeutics |
| 24-Feb | 03:00 - 04:00 PM | New Practices in Early Phase Drug Discovery | PROTACs: A Chemistry Journey of Protein Degraders | Jie Jack Li, PhD Vice President, Discovery Chemistry at ChemPartner |
| 24-Feb | 03:00 - 04:00 PM | Innovative Biomarkers in Drug Development | Supporting Biomarker Discovery One Cell at a Time - Single cell analysis solutions that drive results and insights | Leif Schauer, PhD Director, Global Product Management, QIAGEN Joseph Pearson, PhD Global Product Manger, QIAGEN Digital Insights |
| 24-Feb | 04:30 - 05:30 PM | | Novel Solutions for High Throughput Antibody and Protein Purification Using Magnetic Beads Platform | Nishant Saxena, PhD Product Manager, GenScript |

| | | | | |
|--------|------------------|--|--|---|
| 24-Feb | 12:00 - 12:45 AM | Modern Approaches to Discovery, Preclinical and Clinical Lab Operations in COVID-19 Age | COVID's Impact on Life Sciences Recruiting | Don Alexander, CPC, CFP® President and Managing Director, GeneCoda |
| 24-Feb | 12:00 - 12:45 AM | Novel Advancements to Clinical Development | Evolution of a Platform-Based Non-Clinical Safety Assessment Approach for Vaccines | Joseph J. Senn, PhD, DABT Vice President, Nonclinical Sciences, Moderna |
| 24-Feb | 12:00 - 12:45 AM | Innovative Biomarkers in Drug Development | Lipidomics and Lipidomics in Research | Dr. Christian Klose CTO, Lipotype GmbH |
| 24-Feb | 12:00 - 12:45 AM | Innovative Biomarkers in Drug Development | Multi-diagnostic approaches for patient selection in immuno-oncology | Cindy Spittle VP Scientific Affairs, ICON Laboratory Services |
| 24-Feb | 12:00 - 12:45 AM | (3) Modern Approaches to Discovery, Preclinical, and Clinical Lab Operations in the COVID-19 Age | Nonclinical COVID-19 Vaccine Development During a Pandemic | Cynthia Rohde, PhD, DABT Associate Research Fellow, Drug Safety Research and Development, Pfizer, Inc. |
| 24-Feb | 12:00 - 12:45 AM | New Practices in Early Phase Drug Discovery | Preclinical evaluation of novel OT-analogs for the potential treatment of social behavioral deficits | Marsha Pierce, PhD Assistant Professor, Department of Pharmacology, Midwestern University |
| 24-Feb | 12:00 - 12:45 AM | Novel Advancements to Clinical Development | The Comprehensive A.I.-Driven Genomic Landscape for ALS - Implications for Drug Discovery and Development | Mark Kiel, MD, PhD Co-Founder and Chief Science Officer, Genomenon |
| 24-Feb | 12:00 - 12:45 AM | New Practices in Early Phase Drug Discovery | The development and application of TRUPATH biosensors to the study of GPCR pharmacology and functional selectivity | Reid Olsen, PhD, Pharmacology, Head of GPCR Pharmacology Exscientia Ltd |